Cellular and molecular basis of malignant astrocytoma
Cellular and molecular basis of malignant astrocytoma
批准号:
7848078
负责人:
YUAN ZHU
金额:
$30.63万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2011-05-31
关键词:
AccountingAdultAnaplastic astrocytomaApoptosisAstrocytesAstrocytomaBrainCell ProliferationCellsCentral Nervous System NeoplasmsCharacteristicsDevelopmentDiseaseGene MutationGene SilencingGeneticGenetically Engineered MouseGlioblastomaGoalsGrowthHumanImage AnalysisInvadedLesionMagnetic Resonance ImagingMalignant - descriptorMalignant NeoplasmsMediatingModalityModelingMolecularMolecular GeneticsMutant Strains MiceMutationNF1 geneNatureNeoplasmsNeuraxisNeurofibromatosesNeurofibromatosis 1NeuronsOligodendrogliaOperative Surgical ProceduresPhysiologicalPlayPredispositionPrimary Brain NeoplasmsProtein p53RadiationRegulationResearch PersonnelResistanceRoleSolid NeoplasmStagingSystemTP53 geneTestingTetracyclinesTherapeuticTumor Suppressor GenesWorkbasebrain cellbrain tissuecell typechemotherapyinsightmouse modelnerve stem cellnestin proteinneurosurgeryoutcome forecastpreventprogramsrelating to nervous systemresidenceresponsesubventricular zonetraittumortumorigenic
中文摘要
描述(申请人提供):星形细胞瘤是最常见的原发性脑肿瘤,占所有原发性中枢神经系统(CMS)肿瘤的60%以上。最恶性的星形细胞瘤(IV级星形细胞瘤),也称为多形性胶质母细胞瘤(GBM),是最具侵袭性的人类癌症之一,中位生存期不到1年。不幸的是,在过去的20年里,尽管神经外科、放疗和化疗取得了进展,但这种预后并没有显著改变。恶性星形细胞瘤的2个特征在确定该疾病的致死性方面起着重要作用。首先,与大多数人类实体瘤不同,星形细胞瘤即使在低级别阶段也会广泛侵入正常脑组织,这基本上阻碍了手术治疗。其次,低级别星形细胞瘤转化为GBMs的倾向很高,这对目前所有的治疗方式都有抗药性。因此,治疗恶性星形细胞瘤的主要挑战之一是了解星形细胞瘤细胞高度侵袭性的细胞和分子基础。特别是,(1)大脑中哪种细胞类型引起恶性星形细胞瘤仍然难以捉摸,(2)尽管最近在鉴定与恶性星形细胞瘤发展相关的遗传病变方面取得了进展,但关于特定遗传缺陷如何导致星形细胞瘤细胞异常表型特征的见解却出现得较慢。因此,本研究的具体目的是利用遗传、分子和细胞方法来确定成人大脑中的神经干细胞(NSCs)是否是恶性星形细胞瘤的起源细胞。具体而言,我们将确定(1)肿瘤抑制因子p53和1型神经纤维瘤病(NF1)是否在调节成人脑内NSC增殖、凋亡和分化中发挥生理作用;(2)当p53和NF1突变特异性靶向成人脑内NSCs时,是否会诱导恶性星形细胞瘤。
英文摘要
DESCRIPTION (provided by applicant): Astrocytomas are the most common primary brain tumors and account for more than 60% of all primary central nervous system (CMS) neoplasms. The most malignant form of astrocytoma (grade IV astrocytoma), also known as glioblastoma multiforme (GBM), is 1 of the most aggressive human cancers with a median survival of less than 1 year. Unfortunately, this prognosis has not changed significantly over the past 2 decades, despite advances in neurosurgery, radiation and chemotherapy. 2 characteristic features of malignant astrocytomas play a major role in defining the deadly nature of the disease. First, unlike most human solid tumors, astrocytoma cells extensively invade normal brain tissue even at the low-grade stage, which essentially prevents surgical cure. Second, low-grade astrocytomas have a high propensity to transform into GBMs, which are resistant to all of the current therapeutic modalities. Thus, 1 of the major challenges for treating malignant astrocytomas is to understand the cellular and molecular basis that underlies the highly invasive nature of astrocytoma cells. Particularly, (1) it remains elusive what cell type(s) in the brain gives rise to malignant astrocytoma, (2) insights have been slower to emerge regarding how the specific genetic defects contribute to the abnormal phenotypic traits of astrocytoma cells, despite recent advances in the identification of genetic lesions associated with the development of malignant astrocytomas. Thus, the goals of the specific aims described in this proposal is to use genetic, molecular and cellular approaches to determine whether neural stem cells (NSCs) in the adult brain are the cell-of-origin for malignant astrocytoma. Specifically, we will determine (1) whether tumor suppressors p53 and Neurofibromatosis type 1 (NF1) play physiological roles in regulating NSC proliferation, apoptosis and differentiation in the adult brain and (2) whether malignant astrocytoma can be induced when p53 and NF1 mutations are specifically targeted into NSCs in the adult brain.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.cell.2012.06.034
发表时间:
2012-08-17
期刊:
Cell
影响因子:
64.5
作者:
[Wang Y, Kim E, Wang X, Novitch BG, Yoshikawa K, Chang LS, Zhu Y]
通讯作者:
Zhu Y
DOI:
10.1016/j.ccr.2009.04.001
发表时间:
2009-06-02
期刊:
Cancer cell
影响因子:
50.3
作者:
[Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY, Zhu Y]
通讯作者:
Zhu Y
Developmental Origin, Injury and Epigenomic Regulation of NF1-Associated Peripheral Nerve Sheath Tumors
-
批准号:10393638
-
项目类别:
-
资助金额:$70.39万
-
财政年份:2021
-
负责人:YUAN ZHU
-
依托单位:
Developmental Origin, Injury and Epigenomic Regulation of NF1-Associated Peripheral Nerve Sheath Tumors
-
批准号:10219631
-
项目类别:
-
资助金额:$72.33万
-
财政年份:2021
-
负责人:YUAN ZHU
-
依托单位:
Developmental Origin, Injury and Epigenomic Regulation of NF1-Associated Peripheral Nerve Sheath Tumors
-
批准号:10599153
-
项目类别:
-
资助金额:$67.71万
-
财政年份:2021
-
负责人:YUAN ZHU
-
依托单位:
Investigating and targeting pathways of malignant peripheral nerve sheath tumor (MPNST)
-
批准号:10215635
-
项目类别:
-
资助金额:$58.6万
-
财政年份:2019
-
负责人:YUAN ZHU
-
依托单位:
Investigating and Targeting Pathways of Malignant Peripheral Nerve Sheath Tumor (MPNST)
-
批准号:10439466
-
项目类别:
-
资助金额:$58.6万
-
财政年份:2019
-
负责人:YUAN ZHU
-
依托单位:
Children's Tumor Foundation 2014 Neurofibromatosis (NF) Conference
-
批准号:8786019
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2013
-
负责人:YUAN ZHU
-
依托单位:
Identification of therapeutic windows for NF1-related malignant peripheral nerve
-
批准号:8395374
-
项目类别:
-
资助金额:$21.5万
-
财政年份:2012
-
负责人:YUAN ZHU
-
依托单位:
The role of mTORC1 in the development and therapeutic targeting of NF1-associated
-
批准号:8246412
-
项目类别:
-
资助金额:$34.02万
-
财政年份:2011
-
负责人:YUAN ZHU
-
依托单位:
The role of mTORC1 in the development and therapeutic targeting of NF1-associated
-
批准号:8423789
-
项目类别:
-
资助金额:$32.83万
-
财政年份:2011
-
负责人:YUAN ZHU
-
依托单位:
The role of mTORC1 in the development and therapeutic targeting of NF1-associated
-
批准号:8086146
-
项目类别:
-
资助金额:$33.4万
-
财政年份:2011
-
负责人:YUAN ZHU
-
依托单位:
The role of mTORC1 in the development and therapeutic targeting of NF1-associated
-
批准号:8634151
-
项目类别:
-
资助金额:$37.25万
-
财政年份:2011
-
负责人:YUAN ZHU
-
依托单位:
SNP PROFILE OF RADIOSENSITIVE-RELEVANT GENES/ADVERSE REACTION IN PROSTATE CANCER
-
批准号:7719630
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2008
-
负责人:YUAN ZHU
-
依托单位:
Cellular and molecular basis of malignant astrocytoma
-
批准号:7432528
-
项目类别:
-
资助金额:$30.94万
-
财政年份:2006
-
负责人:YUAN ZHU
-
依托单位:
Cellular and molecular basis of malignant astrocytoma
-
批准号:7019857
-
项目类别:
-
资助金额:$31.94万
-
财政年份:2006
-
负责人:YUAN ZHU
-
依托单位:
Cellular and molecular basis of malignant astrocytoma
-
批准号:7223428
-
项目类别:
-
资助金额:$30.94万
-
财政年份:2006
-
负责人:YUAN ZHU
-
依托单位:
Cellular and molecular basis of malignant astrocytoma
-
批准号:7626465
-
项目类别:
-
资助金额:$30.94万
-
财政年份:2006
-
负责人:YUAN ZHU
-
依托单位:
Identification of therapeutic windows for NF1-related malignant peripheral nerve
-
批准号:8725488
-
项目类别:
-
资助金额:$19.54万
-
财政年份:--
-
负责人:YUAN ZHU
-
依托单位:
Identification of therapeutic windows for NF1-related malignant peripheral nerve
-
批准号:8927547
-
项目类别:
-
资助金额:$24.86万
-
财政年份:--
-
负责人:YUAN ZHU
-
依托单位:
Identification of therapeutic windows for NF1-related malignant peripheral nerve
-
批准号:8561218
-
项目类别:
-
资助金额:$19.33万
-
财政年份:--
-
负责人:YUAN ZHU
-
依托单位:
海外基金